MIS-C Treatment: Is IVIG Always Necessary?

Area of Science:

• Pediatric critical care
• Infectious diseases
• Cardiology

Background:

• Pediatric inflammatory multisystem syndrome (MIS-C) is a severe condition linked to SARS-CoV-2.
• Current first-line treatment, intravenous immunoglobulin (IVIG), involves large fluid volumes that can impair cardiac function.
• An alternative early-phase treatment protocol was developed to mitigate these risks.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel MIS-C treatment protocol prioritizing methylprednisolone (MP) over IVIG.
• To assess patient response rates and the need for escalated therapy.
• To analyze cardiac outcomes and intensive care unit (ICU) admission rates.

Main Methods:

• Retrospective analysis of 31 consecutive MIS-C patients treated between April 2020 and April 2021.
• Patients received either high-dose pulse methylprednisolone (MP) (10 mg/kg) or a lower dose (2 mg/kg) as initial therapy.
• Subsequent treatments included Anakinra or MP dose escalation if initial therapy was insufficient.

Main Results:

• 67.7% of patients responded to initial MP treatment.
• 25.8% required Anakinra and 6.5% needed MP dose increase.
• Only one patient (3.2%) required ICU admission and inotropic support; one developed a coronary artery aneurysm.
• IVIG was administered to only four patients.

Conclusions:

• Early initiation of methylprednisolone (MP) therapy can be effective in managing MIS-C.
• Judicious fluid management alongside MP may enhance patient outcomes.
• This protocol potentially reduces the need for IVIG and associated cardiac risks.